[
  "1. ApoE in Alzheimer’s disease pathophysiology and therapeutic strategies",
  "10. Omics sciences for systems biology in Alzheimer’s disease_ State-of-the-art of the evidence",
  "100. Artificial Intelligence for Alzheimer’s Disease Promise or Challenge",
  "11. The Amyloid-β Pathway in Alzheimer’s Disease",
  "12. Emerging diagnostics and therapeutics for Alzheimer disease",
  "13. Clinical diagnosis of Alzheimer's disease recommendations of the International Working Group",
  "14. Advances in Deep Neuropathological Phenotyping of Alzheimer Disease Past, Present, and Future",
  "15. pathological_mechanisms_and_therapeutic_strategies.12",
  "16. Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease Current Evidence and Future Perspectives",
  "17. Tau biomarkers in Alzheimer's disease_ towards implementation in clinical practice and trials",
  "18. A computational model of neurodegeneration in Alzheimer’s disease",
  "19. Reactive astrocytes_ The nexus of pathological and clinical hallmarks of Alzheimer’s disease",
  "2. Alzheimer’s Disease An Update and Insights Into Pathophysiology",
  "20. Alzheimer s   Dementia - 2024 - Jack - Revised criteria for diagnosis and staging of Alzheimer s disease  Alzheimer s",
  "21. Aging, Cellular Senescence, and Alzheimer’s Disease",
  "22. Blood-based biomarkers for Alzheimer's disease_ Current state and future use in a transformed global healthcare landscape",
  "23. Retinal changes in Alzheimer's disease— integrated prospects of imaging, functional and molecular advances",
  "24. The human connectome in Alzheimer disease — relationship to biomarkers and genetics",
  "25. Activation of Wnt β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease",
  "26. Biomarkers used in Alzheimerâ&#x80;&#x99;s disease diagnosis, treatment, and prevention",
  "27. Therapeutic Approach to Alzheimer’s Disease Current Treatments and New Perspectives",
  "28. Alzheimer’s disease and its treatment by different approaches A review",
  "29. Impaired insulin signalling and allostatic load in Alzheimer disease",
  "3. APOE and Alzheimer's disease_ advances in genetics, pathophysiology, and therapeutic approaches",
  "30. Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease",
  "31. Role of Aducanumab in the Treatment of Alzheimer s Disease  Challenges and Opportunities",
  "32. Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau",
  "33. Role of Withaferin A and Its Derivatives in the Management of Alzheimer’s Disease Recent Trends and Future Perspectives",
  "34. Pathogenesis of Alzheimer’s Disease",
  "35. NMDA and AMPA receptors dysregulation in Alzheimer's disease",
  "36. Metformin in Alzheimer’s disease_ An overview of potential mechanisms, preclinical and clinical findings",
  "37. The NLRP3 inflammasome triggers sterile neuroinflammation and Alzheimers disease",
  "38. The essential elements of Alzheimer’s disease",
  "39. Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis",
  "4. The probabilistic model of Alzheimer disease the amyloid hypothesis revised",
  "40. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease a phase 1b, randomized, placebo-controlled trial",
  "41. Alzheimer s   Dementia - 2021 - Simrén - The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer s",
  "42. Journal of Neurochemistry - 2021 - Kumar - Reactive astrogliosis  A friend or foe in the pathogenesis of Alzheimer s",
  "43. Blood phospho-tau in Alzheimer disease analysis, interpretation, and clinical utility",
  "44. Amyloidosis in Alzheimer’s Disease Pathogeny, Etiology, and Related Therapeutic Directions",
  "45. New insights into the genetic etiology of Alzheimer’s disease and related dementias",
  "46. Toward noninvasive brain stimulation 2.0 in Alzheimerâ&#x80;&#x99;s disease",
  "47. Toward noninvasive brain stimulation 2.0 in Alzheimerâ&#x80;&#x99;s disease",
  "48. Alzheimer’s disease – the journey of a healthy brain into organ failure",
  "49. Journal of Neurochemistry - 2021 - Jakaria - Ferroptosis as a mechanism of neurodegeneration in Alzheimer s disease",
  "5. The impact of the microbiota-gut-brain axis on AlzheimerÃ¢Â&#x80;Â&#x99;s disease pathophysiology",
  "50. Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease",
  "51. Anti-Amyloid Immunotherapies for Alzheimer's Disease_ A 2023 Clinical Update",
  "52. Alzheimer's disease associated with Down syndrome_ a genetic form of dementia",
  "53. Advances in the development of new biomarkers for Alzheimer’s disease",
  "54. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease",
  "55. A global view of the genetic basis of Alzheimer disease",
  "56. The promise of microRNA-based therapies in Alzheimer’s disease challenges and perspectives",
  "57. Epigenetics of Alzheimer’s Disease",
  "58. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer’s disease",
  "59. Blood-based biomarkers for Alzheimer’s disease",
  "6. Developing the ATX(N) classification for use across the Alzheimer disease continuum",
  "60. Molecular subtyping of Alzheimer’s disease using RNA sequencing data reveals novel mechanisms and targets",
  "61. Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies",
  "62. Cerebral blood flow in mild cognitive impairment and Alzheimerâ&#x80;&#x99;s disease_ A systematic review and meta-analysis",
  "63. White matter hyperintensity topography in Alzheimer's disease and links to cognition",
  "64. Neuroinflammation in Alzheimer’s Disease Current Progress in Molecular Signaling and Therapeutics",
  "65. Enhancing autophagy in Alzheimer's disease through drug repositioning",
  "66. Role of Monoamine Oxidase Activity in Alzheimer’s Disease An Insight into the Therapeutic Potential of Inhibitors",
  "67. Alzheimer’s Disease Epidemiology and Clinical Progression",
  "68. Intranasal Insulin for Alzheimer’s Disease",
  "69. Deciphering the Roles of Metformin in Alzheimer’s Disease A Snapshot",
  "7. Alzheimer’s Disease as Type 3 Diabetes Common Pathophysiological Mechanisms between Alzheimer’s Disease and Type 2 Diabetes",
  "70. INPP5D expression is associated with risk for Alzheimer's disease and induced by plaque-associated microglia",
  "71. Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET",
  "72. Blood-based biomarkers for Alzheimer's disease_ towards clinical implementation",
  "73. Altered Gut Microbial Metabolites in Amnestic Mild Cognitive Impairment and Alzheimer’s Disease Signals in Host–Microbe Interplay",
  "74. Neuronal excitation_inhibition imbalance_ core element of a translational perspective on Alzheimer pathophysiology",
  "75. Decreased pH in the aging brain and Alzheimer's disease",
  "76. The neuroimmune axis of Alzheimer’s disease",
  "77. APOE Genotype and Alzheimer’s Disease The Influence of Lifestyle and Environmental Factors",
  "78. ER stress and UPR in Alzheimer’s disease mechanisms, pathogenesis, treatments",
  "79. Effects of pre-analytical procedures on blood biomarkers for Alzheimer's pathophysiology, glial activation, and neurodegeneration",
  "8. Neuropathology of Alzheimer's Disease",
  "80. Apoptosis in Alzheimer’s disease insight into the signaling pathways and therapeutic avenues",
  "81. Oxidative Stress and Beta Amyloid in Alzheimer’s Disease. Which Comes First The Chicken or the Egg",
  "82. Insulin Resistance and Diabetes Mellitus in Alzheimer’s Disease",
  "83. Alzheimer's disease",
  "84. The gut microbiome in Alzheimer’s disease what we know and what remains to be explored",
  "85. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease",
  "86. Alzheimer’s Disease An Updated Overview of Its Genetics",
  "87. Mouse Models of Alzheimer’s Disease",
  "88. Hypertension-induced cognitive impairment from pathophysiology to public health",
  "89. Regional A&beta;-tau interactions promote onset and acceleration of Alzheimer's disease tau spreading",
  "9. Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease",
  "90. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease",
  "91. Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer’s Disease",
  "92. Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer’s Disease Review and Meta-Analysis",
  "93. Distinct amyloid-β and tau-associated microglia profiles in Alzheimer’s disease",
  "94. Lecanemab in patients with early Alzheimer’s disease detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study",
  "95. Super-resolution microscopy a closer look at synaptic dysfunction in Alzheimer disease",
  "96. Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome",
  "97. Astrocyte energy and neurotransmitter metabolism in Alzheimer’s disease_ Integration of the glutamate_GABA-glutamine cycle",
  "98. Imaging Techniques in Alzheimer’s Disease A Review of Applications in Early Diagnosis and Longitudinal Monitoring",
  "99. Resting state EEG biomarkers of cognitive decline associated with Alzheimer’s disease and mild cognitive impairment"
]